Trial Profile
A phase II study of cell therapy technology for the treatment of ovarian cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; AV-GBM-1 (Primary) ; Cell therapies (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2016 According to an AiVita Biomedical media release, the US FDA has approved the IND application to begin this trial.
- 21 Jun 2016 According to an AiVita Biomedical media release, the company expects to initiate this trial by the end of 2016.
- 21 Jun 2016 According to an AiVita Biomedical media release, status changed from planning to not yet recruiting.